ZALICUS INC.

AMPEXA

Pharmaceuticals, namely, combination therapeutic compositions for the treatment of immunological diseases, hyperproliferative diseases, cancer, metabolic diseases, neurodegenerative diseases, infectious diseases, viral diseases, autosomal-recessive genetic diseases, and degenerative muscular diseases;

COMBINATORX

Pharmaceuticals, in particular, combination therapeutic compositions in the nature of anti-inflammatories for the treatment of immunological diseases and immunomodulators for the treatment of immunological diseases;COMBINATION PRESCRIPTION;Drug screening, namely, pharmaceutical product evaluation, pharmaceutical research and development, and testing, inspection or research of pharmaceuticals and pharmaceutical drug development services;

COMBINATORX

Pharmaceuticals, in particular, combination therapeutic compositions in the nature of metabolism-modulating therapeutics for the treatment of metabolic diseases;COMBINATION PRESCRIPTION;

CRX

Prescription pharmaceuticals, namely, therapeutic agents and/or combination therapeutic agents for the treatment of an immunoinflammatory disease;

LUVIRA

Pharmaceuticals for the treatment of pain;

SYNAVIVE

Pharmaceuticals, namely, combination therapeutic compositions for the treatment of immunological diseases;

Z

The mark consists of a white letter Z, including a white cross-bar parallel to the top and bottom of the letter, on a blue, circular background, surrounded by a green circular stripe separated from the blue background by a white border.;Pharmaceutical preparations for the treatment or prevention of immuno-inflammatory disease, pain, proliferative disease, or infectious disease; diagnostic preparations for medical purposes;The color(s) white, blue, and green is/are claimed as a feature of the mark.;Medical Services;Medical apparatus, namely, drug delivery devices and systems; apparatus for clinical diagnosis;Pharmaceutical research and development;